Medicus Pharma Ltd. (MDCX) Income Statement
MDCX 2025 at a glance
Fiscal year ended December 31, 2025 · U.S. dollarsMDCX revenue and net income
MDCX profit margins
MDCX growth rates
to 2025| 1 year | 3 years | 5 years | 10 years | |
|---|---|---|---|---|
| Revenue | — | — | — | — |
| Operating income | — | — | — | — |
| Net income | — | — | — | — |
| EPS (diluted) | — | — | — | — |
1-year change and average annual growth (CAGR) over 3, 5 and 10 fiscal years. "—" when a starting value was zero or negative.
MDCX quarterly EPS vs estimates
Medicus Pharma beat the analyst EPS estimate in 1 of the last 8 quarters. Next report: November 13, 2026 (estimate $-8.50).
MDCX income statement
| 2025 | 2024 | 2023 | 2022 | 2021 | 2017 | 2016 | 2015 | 2010 | |
|---|---|---|---|---|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $12.6M |
| Cost of revenue | — | — | — | — | — | $0 | $0 | $0 | $11.3M |
| Gross profit | — | — | — | — | — | $0 | $0 | $0 | $1.3M |
| Research & development | $7.7M | $3.5M | $193,578 | $646,384 | $1.2M | — | — | — | — |
| Sales, general & admin | $17.9M | $7.7M | $2.5M | $332,032 | $258,009 | $136,360 | $5,767 | $3,416 | $1.8M |
| Total operating expenses | $18.4M | $11.2M | $4.7M | $978,416 | $1.4M | $0 | $0 | $0 | $0 |
| Operating income | −$18.4M | −$11.2M | −$4.7M | −$978,416 | −$1.4M | −$136,360 | −$5,767 | −$3,416 | −$505,829 |
| Interest income | — | $104,411 | — | — | — | — | — | — | — |
| Interest expense | $141,260 | $317,542 | $595,544 | $526,825 | $115,406 | $0 | $0 | $0 | $0 |
| Income before taxes | −$25.4M | −$11.2M | −$5.3M | −$1.7M | −$2.1M | −$138,894 | −$5,767 | −$3,416 | −$674,292 |
| Income taxes | — | — | — | — | — | $0 | $0 | $0 | $0 |
| Net income | −$25.4M | −$11.2M | −$5.3M | −$1.7M | −$2.1M | −$138,894 | −$5,767 | −$3,416 | −$693,760 |
| EBITDA | −$25.2M | −$11.2M | $1.8M | −$1.2M | −$1.9M | — | — | — | — |
| EPS (diluted) | −$2.37 | −$0.98 | −$0.23 | −$0.42 | — | — | — | — | — |
| Gross margin | — | — | — | — | — | — | — | — | 10.6% |
| Operating margin | — | — | — | — | — | — | — | — | −4.0% |
| Net margin | — | — | — | — | — | — | — | — | −5.5% |
| Jun '26 | Mar '26 | Dec '25 | Sep '25 | Jun '25 | Mar '25 | Dec '24 | Sep '24 | Jun '24 | Mar '24 | Dec '23 | Sep '23 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Cost of revenue | — | — | — | — | — | — | — | $26,322 | — | — | — | — |
| Gross profit | — | — | — | — | — | — | — | −$26,322 | — | — | — | — |
| Research & development | $4.9M | $2.7M | $2.6M | $10.4M | $1.4M | $2.0M | $1.4M | $777,514 | $1.1M | $316,388 | $34,495 | $40,395 |
| Sales, general & admin | $6.6M | $5.9M | $5.2M | $5.0M | $4.6M | $3.1M | $1.1M | $1.8M | $2.9M | $1.4M | $2.1M | $186,418 |
| Total operating expenses | $8.3M | $6.3M | $7.8M | $15.4M | $6.0M | $5.1M | $2.4M | $3.0M | $4.0M | $1.8M | $1.8M | $226,813 |
| Operating income | −$8.3M | −$6.3M | −$7.8M | −$15.4M | −$6.0M | −$5.1M | −$2.4M | −$3.0M | −$4.0M | −$1.8M | −$1.8M | −$226,813 |
| Interest income | — | $56,561 | — | $11,572 | — | $23,866 | $48,897 | $55,514 | — | $0 | — | $0 |
| Interest expense | $148,541 | $374,712 | $195,662 | — | $0 | $0 | $796,110 | $8,983 | $88,260 | $9,008 | $0 | $306,477 |
| Income before taxes | −$8.4M | −$6.6M | −$8.2M | −$16.0M | −$6.2M | −$5.1M | −$2.3M | −$3.0M | −$4.1M | −$1.8M | −$2.5M | −$3.0M |
| Net income | −$8.4M | −$6.6M | −$8.2M | −$16.0M | −$6.2M | −$5.1M | −$2.3M | −$3.0M | −$4.1M | −$1.8M | −$2.5M | −$3.0M |
| EBITDA | −$8.3M | −$7.0M | −$8.0M | −$16.0M | −$6.2M | −$5.1M | −$1.5M | −$2.9M | −$4.0M | −$1.8M | −$2.5M | −$2.7M |
| EPS (diluted) | −$0.21 | −$0.30 | −$0.44 | −$1.09 | −$0.42 | −$0.42 | −$0.14 | −$0.31 | −$0.37 | −$0.16 | −$0.23 | — |
Quarterly columns are labeled by the month the quarter ended. Figures in U.S. dollars as reported in MDCX's financial statements (latest annual report filed March 25, 2026); data from EODHD. Sales, general & administrative expenses include sales and marketing.
MDCX financial results
Medicus Pharma reported no revenue in fiscal year 2025 (ended December 31, 2025). It had a net loss of $25.4 million. Diluted earnings per share came to −$2.37.
See the MDCX stock overview for the latest quote and news, or the MDCX chart for price history and technical indicators.
MDCX income statement FAQ
Does Medicus Pharma have revenue?
Medicus Pharma reported no revenue for fiscal year 2025, which ended on December 31, 2025.
Is Medicus Pharma profitable?
No. Medicus Pharma reported a net loss of $25.4 million in fiscal 2025.
How much does Medicus Pharma spend on research and development?
Medicus Pharma spent $7.7 million on research and development in fiscal 2025.
What are Medicus Pharma's earnings per share?
Medicus Pharma earned $-2.37 per diluted share in fiscal 2025, compared with $-0.98 a year earlier.
When will Medicus Pharma report its next earnings?
Medicus Pharma is expected to report results for the quarter ending September 30, 2026 on November 13, 2026.
When does Medicus Pharma's fiscal year end?
Medicus Pharma's fiscal year ends in December. The latest annual report covers the year ended December 31, 2025 and was filed on March 25, 2026.